Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.
Ken Lee Chin, Timothy Collier, Stuart Pocock, Bertram Pitt, John JV McMurray, Dirk J van Veldhuisen, Karl Swedberg, John Vincent, Faiez Zannad, Danny Liew
Clin Res Cardiol | Published : 2019
BACKGROUND: Increased resting heart rate is a risk factor for cardiovascular mortality and morbidity. Mineralocorticoid receptor antagonists (MRAs) have been shown to improve cardiac sympathetic nerve activity, reduce heart rate and attenuate left ventricular remodelling. Whether or not the beneficial effects of MRA are affected by heart rate in heart failure patients with reduced ejection fraction (HFREF) is unclear. METHODS: We undertook a secondary analysis of data from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure study to assess if clinical outcomes, as well as the efficacy of eplerenone, varied according to heart rate at baseline. RESULTS: High res..View full abstract